Advicenne S.A. (EPA:ALDVI)

Market Cap	23.86M +33.7%
Revenue (ttm)	6.40M +21.6%
Net Income	-9.53M
EPS	-0.65
Shares Out	14.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,325
Open	1.720
Previous Close	1.640
Day's Range	1.658 - 1.728
52-Week Range	0.804 - 2.350
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Par...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 11
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2025, Advicenne's revenue was 6.40 million, an increase of 21.56% compared to the previous year's 5.27 million. Losses were -9.53 million, 47.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 3, 2026

Data Sources Report a data error